Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers available to (1) accurately diagnose these diseases; (2) enrich and stratify patient cohorts; (3) demonstrate target engagement for novel therapeutics; and (4) reliably monitor disease progression and response to treatment. While currently available biomarkers have helped to accelerate clinical trials, most are either expensive, invasive, or both, and only provide information on a small number of disease targets. Therefore, additional biomarkers are needed to provide a more complete picture of the disease.
To that end, the Alzheimer's Drug Delivery Foundation has issued a Request for Proposals to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.
Grants of up to $300,000 over two years will be awarded in support of projects related to the development of biomarkers previously identified in samples from well-characterized human subjects. Priority biomarker areas include companion biomarkers, neuroimaging, CSF and blood-based biomarkers, and functional activity measures.
Eligible applicants include academic investigators seeking to create and support innovative biomarker programs in academic medical centers and universities, and biotechnology companies with programs dedicated to Alzheimer's disease biomarker development. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.
Letters of Intent must be received no later than October 12. Upon review, selected applicants will be invited to submit a full proposalsby November 9, 2018.
For complete program guidelines and proposal submission instructions, see the Alzheimer's Drug Discovery Foundation website.